| Name | Title | Contact Details |
|---|
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.
Validation Technologies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
United Pharmacists Enterprises Ltd is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Accent Urgent Care and After Hours Pediatrics is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Gynesonics our mission is to design and develop new and advanced technologies for improving women`s health. We are focused on providing an incision-free option to women and the physicians who care for them, in treating symptomatic uterine fibroids. We are initiating a pivotal IDE trial in the United States to verify the safety and efficacy of the Sonata system, in preserving the uterus while treating those fibroids associated with abnormal uterine bleeding that are difficult to treat with existing technology and surgical techniques. We are committed to providing women with a safe and effective incision-free alternative to the invasive surgical techniques of hysterectomy or myomectomy for their severe menstrual symptoms associated with fibroids.